Ascendis Pharma A/S

Ascendis Pharma Misses on EPS, Stock Down 1.74%

Ascendis Pharma reported a larger-than-expected loss per share, which contributed to a decline in its stock price by 1.74%. The lack of revenue figures and guidance may raise concerns among investors about the company's current performance and future outlook. The absence of management commentary further adds to the uncertainty surrounding the stock.